Literature DB >> 24561826

Construction and characterization of adenoviral vectors for the delivery of TALENs into human cells.

Maarten Holkers1, Toni Cathomen2, Manuel A F V Gonçalves3.   

Abstract

Transcription activator-like effector nucleases (TALENs) are designed to cut the genomic DNA at specific chromosomal positions. The resulting DNA double strand break activates cellular repair pathways that can be harnessed for targeted genome modifications. TALENs thus constitute a powerful tool to interrogate the function of DNA sequences within complex genomes. Moreover, their high DNA cleavage activity combined with a low cytotoxicity make them excellent candidates for applications in human gene therapy. Full exploitation of these large and repeat-bearing nucleases in human cell types will benefit largely from using the adenoviral vector (AdV) technology. The genetic stability and the episomal nature of AdV genomes in conjunction with the availability of a large number of AdV serotypes able to transduce various human cell types make it possible to achieve high-level and transient expression of TALENs in numerous target cells, regardless of their mitotic state. Here, we describe a set of protocols detailing the rescue, propagation and purification of TALEN-encoding AdVs. Moreover, we describe procedures for the characterization and quantification of recombinant viral DNA present in the resulting AdV preparations. The protocols are preceded by information about their underlying principles and applied in the context of second-generation capsid-modified AdVs expressing TALENs targeted to the AAVS1 "safe harbor" locus on human chromosome 19.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adenoviral vectors; Designer nucleases; Gene editing; Genome engineering; TALENs; Transcription activator-like effector nucleases

Mesh:

Substances:

Year:  2014        PMID: 24561826     DOI: 10.1016/j.ymeth.2014.02.017

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  18 in total

1.  Adenoviral vector DNA for accurate genome editing with engineered nucleases.

Authors:  Maarten Holkers; Ignazio Maggio; Sara F D Henriques; Josephine M Janssen; Toni Cathomen; Manuel A F V Gonçalves
Journal:  Nat Methods       Date:  2014-08-24       Impact factor: 28.547

Review 2.  Non-viral delivery of genome-editing nucleases for gene therapy.

Authors:  M Wang; Z A Glass; Q Xu
Journal:  Gene Ther       Date:  2016-10-31       Impact factor: 5.250

Review 3.  CRISPR-Cas9 genome engineering: Treating inherited retinal degeneration.

Authors:  Erin R Burnight; Joseph C Giacalone; Jessica A Cooke; Jessica R Thompson; Laura R Bohrer; Kathleen R Chirco; Arlene V Drack; John H Fingert; Kristan S Worthington; Luke A Wiley; Robert F Mullins; Edwin M Stone; Budd A Tucker
Journal:  Prog Retin Eye Res       Date:  2018-03-22       Impact factor: 21.198

Review 4.  TALEN gene editing takes aim on HIV.

Authors:  Ronald Benjamin; Bradford K Berges; Antonio Solis-Leal; Omoyemwen Igbinedion; Christy L Strong; Martin R Schiller
Journal:  Hum Genet       Date:  2016-05-12       Impact factor: 4.132

5.  Damaging the Integrated HIV Proviral DNA with TALENs.

Authors:  Christy L Strong; Horacio P Guerra; Kiran R Mathew; Nervik Roy; Lacy R Simpson; Martin R Schiller
Journal:  PLoS One       Date:  2015-05-06       Impact factor: 3.240

6.  Novel lentiviral vectors with mutated reverse transcriptase for mRNA delivery of TALE nucleases.

Authors:  Ulrike Mock; Kristoffer Riecken; Belinda Berdien; Waseem Qasim; Emma Chan; Toni Cathomen; Boris Fehse
Journal:  Sci Rep       Date:  2014-09-18       Impact factor: 4.379

7.  Genetic rearrangements of variable di-residue (RVD)-containing repeat arrays in a baculoviral TALEN system.

Authors:  Cia-Hin Lau; Haibao Zhu; Johan Chin-Kang Tay; Zhendong Li; Felix Chang Tay; Can Chen; Wee-Kiat Tan; Shouhui Du; Vic-Ki Sia; Rui-Zhe Phang; Shin-Yi Tang; Chiyun Yang; Zhixia Chi; Chieh-Ching Liang; Er Ning; Shu Wang
Journal:  Mol Ther Methods Clin Dev       Date:  2014-10-29       Impact factor: 6.698

8.  Adenoviral vector delivery of RNA-guided CRISPR/Cas9 nuclease complexes induces targeted mutagenesis in a diverse array of human cells.

Authors:  Ignazio Maggio; Maarten Holkers; Jin Liu; Josephine M Janssen; Xiaoyu Chen; Manuel A F V Gonçalves
Journal:  Sci Rep       Date:  2014-05-29       Impact factor: 4.379

Review 9.  Engineered Viruses as Genome Editing Devices.

Authors:  Xiaoyu Chen; Manuel A F V Gonçalves
Journal:  Mol Ther       Date:  2015-09-04       Impact factor: 11.454

10.  Reactivation of Latent HIV-1 Expression by Engineered TALE Transcription Factors.

Authors:  Pedro Perdigão; Thomas Gaj; Mariana Santa-Marta; Carlos F Barbas; Joao Goncalves
Journal:  PLoS One       Date:  2016-03-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.